Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04957511 · ClinicalTrials.gov registry record
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
A clinical trial of Gynecologic Cancer and Gut Microbiome, sponsored by Viome.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT04957511 is a study of Gynecologic Cancer and Gut Microbiome that is actively recruiting participants, run by Viome. The registered enrollment target is 30 participants, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04957511, a study of Gynecologic Cancer and Gut Microbiome, is actively recruiting participants, sponsored by Viome.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation. Additional samples are collected for results analysis.
Conditions Studied
Study Locations (1)
Florida
- AdventHealth Cancer Institute - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04957511
The ClinicalTrials.gov registry entry for NCT04957511 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Viome, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Gynecologic Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04957511 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04957511 about?
NCT04957511 is a clinical study titled "Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy". 30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation. Additional samples are collected for results analysis.
What is the current status of trial NCT04957511?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2021-06-29. Estimated completion is 2026-06.
What conditions does trial NCT04957511 study?
This clinical trial studies the following conditions: Gynecologic Cancer, Gut Microbiome, Immunotherapy.
Who is sponsoring clinical trial NCT04957511?
This trial is sponsored by Viome, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04957511 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
RECRUITING
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
RECRUITING · NA
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.